Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
City of Hope Medical Center
National Cancer Institute (NCI)
AbbVie
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Genmab
Seagen Inc.
Sun Yat-sen University
Gustave Roussy, Cancer Campus, Grand Paris
AstraZeneca
Neonc Technologies, Inc.
Shanghai Chest Hospital
Pfizer
AstraZeneca
Second Affiliated Hospital of Nanchang University
Eli Lilly and Company
Shanghai Hengrui Pharmaceutical Co., Ltd.
Bristol-Myers Squibb
Cedars-Sinai Medical Center
Xinqiao Hospital of Chongqing
Dizal Pharmaceuticals
Shanghai Junshi Bioscience Co., Ltd.
Maastricht University Medical Center
Henan Cancer Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Sun Yat-sen University
Sun Yat-sen University
Ruijin Hospital
Sun Yat-sen University
Taiho Pharmaceutical Co., Ltd.
Mabscale, LLC
Hunan Province Tumor Hospital
Second Affiliated Hospital of Guangzhou Medical University
Second Affiliated Hospital of Guangzhou Medical University
Hunan Province Tumor Hospital
Hunan Province Tumor Hospital
Hunan Province Tumor Hospital
Lebanese University
N.N. Petrov National Medical Research Center of Oncology
Shanghai Pulmonary Hospital, Shanghai, China